Venezuelan equine encephalitis virus
(VEEV) is an emerging pathogenic
alphavirus that can cause significant disease in humans. Given the
absence of therapeutic options available and the significance of VEEV
as a weaponized agent, an optimization effort was initiated around
a quinazolinone screening hit 1 with promising cellular
antiviral activity (EC50 = 0.8 μM), limited cytotoxic
liability (CC50 > 50 μM), and modest in vitro
efficacy
in reducing viral progeny (63-fold at 5 μM). Scaffold optimization
revealed a novel rearrangement affording amidines, specifically compound 45, which was found to potently inhibit several VEEV strains
in the low nanomolar range without cytotoxicity (EC50 =
0.02–0.04 μM, CC50 > 50 μM) while
limiting
in vitro viral replication (EC90 = 0.17 μM). Brain
exposure was observed in mice with 45. Significant protection
was observed in VEEV-infected mice at 5 mg kg–1 day–1 and viral replication appeared to be inhibited through
interference of viral nonstructural proteins.